Diseases
Companies
Products
Productz
Mechanisms of Action
Sites
RD125
/
IASO BIO
Welcome,
Profile
Billing
Logout
Diseases
Trials
Trials
News
|
|||||||||
RD125
/
Huazhong University of Science and Technology, IASO BIO
New P1 trial, CAR T-Cell Therapy:
Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies
(clinicaltrials.gov) - Feb 22, 2021
P1
, N=18, Not yet recruiting,
Sponsor: Huazhong University of Science and Technology